Compare Dominion Energy Inc (D) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dominion Energy Inc vs Merck & Co., Inc. — how do they compare? Dominion Energy Inc trades at $68.19 (market cap $59.90B), while Merck & Co., Inc. trades at $133.5 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 5.4× Dominion Energy Inc's market cap, and Dominion Energy Inc pays the higher dividend (3.92%). Which is the better fit depends on your goals.
| D | MRK | |
|---|---|---|
Market Cap | $59.90B | $321.77B |
Sector | Utilities | Health |
52-Week High | $71.67 | $131.84 |
52-Week Low | $57.08 | $77.60 |
Enterprise Value | $114.01B | $368.53B |
Dividend Yield | 3.92% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dominion Energy (D) trades at $67.96, up 1.23% today, with a bearish technical signal and mixed analyst sentiment. Recent Q2 2026 earnings beat estimates ($0.79 vs. $0.681 expected), driven by Virginia utility strength and data center demand, while revenue grew to $16.51B in 2025. The stock faces headwinds from high debt levels and rising operating costs, offset by stable dividends and reaffirmed 2026 guidance.
The outlook is cautious; Dominion benefits from essential service demand and dividend consistency, but valuation appears fair with a P/E of 23.56, and risks include execution on capital projects and regulatory pressures. Analyst consensus leans Hold with a $70.43 price target, suggesting limited near-term upside from current levels.
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
